Management of chronic hepatitis B: consensus guidelines.

Evidence-based clinical guidelines for immigrants and refugees. CMAJ (2010) 3.57

Prevention of vertical transmission of hepatitis B: an observational study. Ann Intern Med (2014) 2.05

Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines. Can J Gastroenterol (2012) 1.27

The metabolomic window into hepatobiliary disease. J Hepatol (2013) 1.24

Hepatitis B learning needs assessment of family medicine trainees in Canada: results of a nationwide survey. Can J Gastroenterol (2011) 1.19

Hepatitis B screening and vaccination strategies for newly arrived adult Canadian immigrants and refugees: a cost-effectiveness analysis. PLoS One (2013) 0.95

Lower baseline ALT cut-off values and HBV DNA levels better differentiate HBeAg- chronic hepatitis B patients from inactive chronic carriers. World J Gastroenterol (2009) 0.93

Hepatitis B screening before chemotherapy: a survey of practitioners' knowledge, beliefs, and screening practices. J Oncol Pract (2012) 0.89

Management of hepatitis B: a longitudinal national survey - impact of the Canadian Hepatitis B Consensus Guidelines. Can J Gastroenterol (2010) 0.89

Screening for hepatitis B surface antigen before chemotherapy: current practice and opportunities for improvement. Curr Oncol (2010) 0.87

A cross-border comparison of hepatitis B testing among chinese residing in Canada and the United States. Asian Pac J Cancer Prev (2009) 0.84

Structural Analysis of Monomeric RNA-Dependent Polymerases: Evolutionary and Therapeutic Implications. PLoS One (2015) 0.84

The Role of Antiviral Therapy for HBV-Related Hepatocellular Carcinoma. Int J Hepatol (2011) 0.83

Reassessing the role for lamivudine in chronic hepatitis B infection: a four-year cohort analysis. Can J Gastroenterol (2012) 0.83

Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis. PLoS One (2015) 0.82

Disease burden of chronic hepatitis B among immigrants in Canada. Can J Gastroenterol (2013) 0.81

Orthotopic liver transplantation and what to do during follow-up: recommendations for the practitioner. Nat Clin Pract Gastroenterol Hepatol (2008) 0.81

Canadian trends in liver cancer: a brief clinical and epidemiologic overview. Curr Oncol (2013) 0.80

Prevention and Management of Chronic Hepatitis B. Int J Prev Med (2014) 0.79

Characterization of Acute and Chronic Hepatitis B Virus Genotypes in Canada. PLoS One (2015) 0.78

Canadian patients with chronic hepatitis B cannot access appropriate drug treatments: a call for change. Can J Gastroenterol (2011) 0.76

Model of life expectancy of chronic hepatitis B carriers in an endemic region. J Epidemiol (2009) 0.75

Hepatitis B virus and its sexually transmitted infection - an update. Microb Cell (2016) 0.75

Management and treatment of hepatitis B virus in patients with HIV infection: A practical guide for health care professionals. Can J Infect Dis Med Microbiol (2011) 0.75

The expression of TLR-9, CD86, and CD95 phenotypes in circulating B cells of patients with chronic viral hepatitis B or C before and after antiviral therapy. Mediators Inflamm (2015) 0.75

Recent advances in managing hepatitis B. F1000 Med Rep (2010) 0.75

Information technology and infectious diseases: Promise and pitfalls. Can J Infect Dis Med Microbiol (2007) 0.75

A Cost-Utility and Cost-Effectiveness Analysis of Different Oral Antiviral Medications in Patients With HBeAg-Negative Chronic Hepatitis B in Iran: An Economic Microsimulation Decision Model. Hepat Mon (2016) 0.75

Public health response to a large-scale endoscopy infection control lapse in a nonhospital clinic. Can J Infect Dis Med Microbiol (2015) 0.75

Management of hepatocellular carcinoma. Hepatology (2005) 27.42

Hepatitis B virus infection. N Engl J Med (1997) 14.50

Chronic hepatitis B. Hepatology (2007) 13.75

Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med (2002) 10.78

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA (2006) 10.58

Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med (2004) 10.31

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med (1998) 9.03

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med (2006) 7.35

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med (2005) 7.18

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology (2006) 6.67

Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med (2002) 6.20

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med (2003) 5.97

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med (2006) 5.65

A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep (2006) 5.63

HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet (2002) 5.60

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med (2004) 5.40

Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med (1999) 5.32

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med (1990) 4.53

Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol (2001) 4.46

Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology (2003) 4.33

Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ (2004) 4.22

Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology (2004) 4.12

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med (2003) 4.12

Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med (2002) 3.91

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology (2006) 3.80

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology (2004) 3.70

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis (2003) 3.69

Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology (1987) 3.65

Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med (1993) 3.53

Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst (2005) 3.48

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med (1996) 3.41

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet (2005) 3.33

Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology (2003) 3.30

Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology (2006) 3.14

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology (2004) 2.97

Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS (1997) 2.88

Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology (2006) 2.84

Screening for chronic hepatitis B among Asian/Pacific Islander populations--New York City, 2005. MMWR Morb Mortal Wkly Rep (2006) 2.82

Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology (2007) 2.78

Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology (2006) 2.68

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother (2004) 2.67

Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med (2001) 2.57

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut (2000) 2.55

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology (2001) 2.51

Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut (2005) 2.49

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int (2005) 2.46

EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol (2003) 2.37

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology (1999) 2.36

Hepatitis B e antigen-negative chronic hepatitis B. Hepatology (2001) 2.29

Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology (2006) 2.28

Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol (2005) 2.26

Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology (2006) 2.22

Long term effect of alpha interferon in children with chronic hepatitis B. Gut (2000) 2.21

Classifying hepatitis B virus genotypes. Intervirology (2003) 2.20

Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology (2004) 2.17

Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology (1999) 2.16

An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sang (2001) 2.15

A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology (2005) 2.08

Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther (2006) 2.04

Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol (2006) 2.03

Viral hepatitis guidelines in hemodialysis and transplantation. Am J Transplant (2004) 2.01

Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology (2004) 2.01

Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology (2002) 2.01

Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat (2003) 1.97

Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology (2006) 1.97

Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology (2006) 1.93

Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med (1991) 1.92

Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol (2003) 1.87

Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther (2005) 1.85

Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut (2000) 1.84

Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol (1997) 1.83

Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol (2002) 1.81

Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology (2005) 1.80

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology (2000) 1.78

A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med (2006) 1.67

Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol (2005) 1.63

Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology (1997) 1.62

Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology (2005) 1.57

Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol (2006) 1.56

Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology (2000) 1.55

Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol (2004) 1.55

Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat (2003) 1.53

Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients. J Clin Virol (2003) 1.53

Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med (1990) 1.53

Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology (2003) 1.48

Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother (2006) 1.45

Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer (1999) 1.43

Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol (1994) 1.40

Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology (1986) 1.38

Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology (1991) 1.35

Evaluation of the COBAS AmpliPrep-total nucleic acid isolation-COBAS TaqMan hepatitis B virus (HBV) quantitative test and comparison to the VERSANT HBV DNA 3.0 assay. J Clin Microbiol (2006) 1.35

Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet (2001) 1.32

Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology (2006) 1.32

Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med (2004) 1.29

Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology (2006) 1.28

Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology (1997) 1.28

Routine detection and quantification of hepatitis B virus DNA in clinical laboratories: performance of three commercial assays. J Virol Methods (2000) 1.26

Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol (2006) 1.23

Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood. Gastroenterology (1990) 1.23

Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res (2004) 1.22

Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis (2005) 9.23

Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci (2006) 3.85

Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med (2003) 3.78

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med (2015) 3.16

Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci U S A (2004) 2.88

Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology (2014) 2.56

Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5' untranslated region sequences. J Clin Microbiol (2007) 2.55

Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med (2009) 2.21

Management of chronic hepatitis C: consensus guidelines. Can J Gastroenterol (2007) 2.06

Pathogenicity determinants in smut fungi revealed by genome comparison. Science (2010) 2.03

Ectopic varices. Gastrointest Endosc (2011) 1.75

Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology (2011) 1.71

Pharmacological response of human cardiomyocytes derived from virus-free induced pluripotent stem cells. Cardiovasc Res (2011) 1.67

Occult hepatitis B virus infection in a North American community-based population. J Hepatol (2005) 1.64

Health care costs associated with hepatocellular carcinoma: a population-based study. Hepatology (2013) 1.63

CCancer: a bird's eye view on gene lists reported in cancer-related studies. Nucleic Acids Res (2010) 1.62

Sildenafil preserves intracorporeal smooth muscle after radical retropubic prostatectomy. J Urol (2004) 1.62

Genome comparison of barley and maize smut fungi reveals targeted loss of RNA silencing components and species-specific presence of transposable elements. Plant Cell (2012) 1.61

Clostridium difficile colitis: increasing incidence, risk factors, and outcomes in solid organ transplant recipients. Transplantation (2012) 1.52

Endophytic life strategies decoded by genome and transcriptome analyses of the mutualistic root symbiont Piriformospora indica. PLoS Pathog (2011) 1.52

G-CSF for stem cell therapy in acute myocardial infarction: friend or foe? Cardiovasc Res (2010) 1.47

Hepatic portal venous gas: a report of two cases and a review of the epidemiology, pathogenesis, diagnosis and approach to management. Can J Gastroenterol (2007) 1.46

BACE1 deficiency causes altered neuronal activity and neurodegeneration. J Neurosci (2010) 1.45

Bioabsorbable vascular scaffold overexpansion: insights from in vitro post-expansion experiments. EuroIntervention (2016) 1.45

Ex vivo differentiation of human adult bone marrow stem cells into cardiomyocyte-like cells. Biochem Biophys Res Commun (2004) 1.43

DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4. Liver Int (2014) 1.42

Retracted Myoblast transplantation for cardiac repair: from automyoblast to allomyoblast transplantation. Ann Thorac Surg (2008) 1.39

In regard to RTOG sarcoma radiation oncologists reach consensus on gross tumor volume and clinical target volume on computed tomographic images for preoperative radiotherapy of primary soft tissue sarcoma of extremity in Radiation Therapy Oncology Group studies: in regard to Wang et al (Int J Radiat Oncol Biol Phys 2011;81:e525-e528). Int J Radiat Oncol Biol Phys (2012) 1.37

A domain interaction map based on phylogenetic profiling. J Mol Biol (2004) 1.35

A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. Transplantation (2010) 1.35

Incomplete stent apposition causes high shear flow disturbances and delay in neointimal coverage as a function of strut to wall detachment distance: implications for the management of incomplete stent apposition. Circ Cardiovasc Interv (2014) 1.33

The Negatome database: a reference set of non-interacting protein pairs. Nucleic Acids Res (2009) 1.32

GeneSet2miRNA: finding the signature of cooperative miRNA activities in the gene lists. Nucleic Acids Res (2009) 1.31

Generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy. Eur Heart J (2012) 1.24

Hepatitis E in new zealand. J Gastroenterol Hepatol (2007) 1.23

Involvement in teaching improves learning in medical students: a randomized cross-over study. BMC Med Educ (2009) 1.22

TICL--a web tool for network-based interpretation of compound lists inferred by high-throughput metabolomics. FEBS J (2009) 1.21

Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications. Biochem Biophys Res Commun (2009) 1.20

Choledochal cysts: analysis of disease pattern and optimal treatment in adult and paediatric patients. HPB (Oxford) (2007) 1.20

Disrupted-in-Schizophrenia-1 expression is regulated by beta-site amyloid precursor protein cleaving enzyme-1-neuregulin cascade. Proc Natl Acad Sci U S A (2010) 1.18

Mesenchymal stem cell-derived exosomes promote hepatic regeneration in drug-induced liver injury models. Stem Cell Res Ther (2014) 1.15

Electrophysiology of human cardiac atrial and ventricular telocytes. J Cell Mol Med (2014) 1.14

CDK1 inhibitors antagonize the immediate apoptosis triggered by spindle disruption but promote apoptosis following the subsequent rereplication and abnormal mitosis. Cell Cycle (2008) 1.12

Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells. Int J Cardiol (2013) 1.11

Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults. PLoS One (2011) 1.09

One-step derivation of cardiomyocytes and mesenchymal stem cells from human pluripotent stem cells. Stem Cell Res (2012) 1.06

Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res (2014) 1.05

Current trends in diagnostic biomarkers of acute coronary syndrome. Ann Acad Med Singapore (2010) 1.05

Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. Cancer Res (2007) 1.04

Analysis and outcomes of right lobe hepatectomy in 101 consecutive living donors. Am J Transplant (2005) 1.04

Consensus statements from a multidisciplinary expert panel on the utilization and application of a liver-specific MRI contrast agent (gadoxetic acid). AJR Am J Roentgenol (2015) 1.03

Influence of socioeconomic status on survival of hepatocellular carcinoma in the Ontario population; a population-based study, 1990-2009. PLoS One (2012) 1.02

Specificity in substrate and cofactor recognition by the N-terminal domain of the chaperone ClpX. Proc Natl Acad Sci U S A (2006) 1.02

Characteristics of primary biliary cirrhosis in British Columbia's First Nations population. Can J Gastroenterol (2005) 1.01

Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation (2009) 1.00

Pretransplantation α-fetoprotein slope and milan criteria: strong predictors of hepatocellular carcinoma recurrence after transplantation. Transplantation (2013) 0.99

Treatment of hepatitis C in children: a systematic review. PLoS One (2010) 0.99

Liver transplantation for incidental cholangiocarcinoma: analysis of the Canadian experience. Liver Transpl (2005) 0.98

Noninvasive diagnosis of liver fibrosis: The importance of being reimbursed. Can J Gastroenterol Hepatol (2015) 0.97

Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation. Can J Gastroenterol (2007) 0.97

Monitoring of polyomavirus BK virus viruria and viremia in renal allograft recipients by use of a quantitative real-time PCR assay: one-year prospective study. J Clin Microbiol (2007) 0.96

PLIPS, an automatically collected database of protein lists reported by proteomics studies. J Proteome Res (2009) 0.96

Liver transplantation for hepatic epithelioid hemangioendothelioma: the Canadian multicentre experience. Can J Gastroenterol (2008) 0.93

Cell delivery and tracking in post-myocardial infarction cardiac stem cell therapy: an introduction for clinical researchers. Heart Fail Rev (2010) 0.93

Living-donor right hepatectomy with or without inclusion of middle hepatic vein: comparison of morbidity and outcome in 56 patients. Am J Transplant (2004) 0.93

The difference in the fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to the difference in donor age. Liver Transpl (2008) 0.92

Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection. Gastroenterology (2013) 0.92

Hemodynamic contribution of stem cell scaffolding in acute injured myocardium. Tissue Eng Part A (2012) 0.92

Radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma. Transpl Int (2009) 0.92

The use of donor and recipient screening for toxoplasma in the era of universal trimethoprim sulfamethoxazole prophylaxis. Transplantation (2008) 0.91

Early changes in kidney function predict long-term chronic kidney disease and mortality in patients after liver transplantation. Transplantation (2011) 0.91

Identification and characterization of calcium sparks in cardiomyocytes derived from human induced pluripotent stem cells. PLoS One (2013) 0.90

Complexity and health coaching: synergies in nursing. Nurs Res Pract (2013) 0.89

Recovery of locked-in syndrome following liver transplantation with calcineurin inhibitor cessation and supportive treatment. Am J Case Rep (2013) 0.88

Differential effect of myocardial matrix and integrins on cardiac differentiation of human mesenchymal stem cells. Differentiation (2010) 0.88

Epidemiology and treatment of hepatitis C genotypes 5 and 6. Can J Gastroenterol (2013) 0.87

A randomized, controlled trial of daclizumab vs anti-thymocyte globulin induction for lung transplantation. J Heart Lung Transplant (2007) 0.87

The kinetics of p53 activation versus cyclin E accumulation underlies the relationship between the spindle-assembly checkpoint and the postmitotic checkpoint. J Biol Chem (2008) 0.87

The mystery of primary biliary cirrhosis in British Columbia's First Nations people. Int J Circumpolar Health (2004) 0.86

Rapid determination of vertebral fat fraction over a large range of vertebral bodies. J Med Imaging Radiat Oncol (2013) 0.85

Hepatitis B and the infected health care worker: public safety at what cost? Can J Gastroenterol (2012) 0.85

Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma. Mol Cancer (2012) 0.85

iPSC-derived human mesenchymal stem cells improve myocardial strain of infarcted myocardium. J Cell Mol Med (2014) 0.85

Liquid chromatography/tandem mass spectrometry for the determination of carbamazepine and its main metabolite in rat plasma utilizing an automated blood sampling system. J Pharm Biomed Anal (2005) 0.85

Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up. Liver Transpl (2003) 0.85

Pharmacoelectrophysiology of viral-free induced pluripotent stem cell-derived human cardiomyocytes. Toxicol Sci (2012) 0.85

Saudi Gastroenterology Association guidelines for the diagnosis and management of hepatocellular carcinoma: summary of recommendations. Ann Saudi Med (2006) 0.84

Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin. Can J Gastroenterol (2006) 0.84

An assessment of donor-to-recipient transmission patterns of human cytomegalovirus by analysis of viral genomic variants. J Infect Dis (2009) 0.84